Cluster headache, hypothalamus, and orexin

Current Pain and Headache Reports

Volumn 13, Issue 2, 2009, Pages 147-154

  Holland, Philip R ^a   Goadsby, Peter J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; ACT 078537; CYCLOSOMATOSTATIN; HYPOTHALAMUS HORMONE; NEUROTRANSMITTER; OCTREOTIDE; OREXIN; OREXIN A; OREXIN B; PEPTIDE HORMONE; PLACEBO; RECEPTOR BLOCKING AGENT; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; AUTONOMIC DYSFUNCTION; AUTONOMIC INNERVATION; AUTONOMIC NERVOUS SYSTEM; BRAIN DEPTH STIMULATION; CIRCADIAN RHYTHM; CIRCANNUAL RHYTHM; CLINICAL TRIAL; CLUSTER HEADACHE; DISEASE SEVERITY; DRUG MECHANISM; HUMAN; HYPOTHALAMUS; LOW DRUG DOSE; MIGRAINE; NARCOLEPSY; NEUROMODULATION; NOCICEPTION; NONHUMAN; PARASYMPATHETIC FUNCTION; PATHOPHYSIOLOGY; PRIMARY HEADACHE; RECURRENT DISEASE; REVIEW; SLEEP DISORDER; TRIGEMINAL NERVE; TRIGEMINUS NEURALGIA;

CLUSTER HEADACHE; HUMANS; HYPOTHALAMUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS; PAIN; SYNAPTIC TRANSMISSION;

EID: 63249127923     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-009-0025-x     Document Type: Review

References (60)

1. Headache Classification Committee of the International Headache Society: The International Classification of Headache Disorders 2nd ed. Cephalalgia 2004, 24(Suppl 1): 1-160.
2. Drummond PD: Mechanisms of autonomic disturbance in the face during and between attacks of cluster headache. Cephalalgia 2006, 26:633-641.
3. Holland P, Goadsby PJ: The hypoPhalamic orexinergic system: pain and primary headaches. Headache 2007, 47:951-962.
4. Obermann M, Yoon MS, Dommes P, et al.: Prevalence of trigeminal autonomic symptoms in migraine: A population-based study. Cephalalgia 2007, 27:504-509.
5. Frese A, Evers S, May A: Autonomic activation in experimental trigeminal pain. Cephalalgia 2003, 23:67-68.
6. Hastings MHC Reddy AB, Maywood ES: A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci 2003, 4:649-661.
7. Moore RY: Organization and function of a central nervous system circadian oscillator: The suprachiasmatic hypothalamic nucleus. Fed Proc 1983, 42:2783-2789.
8. Buijs RM, Wortel J, Van Heerikhuize JJ, et al.: Anatomical and functional demonstration of a multisynaptic suprachiasmatic nucleus adrenal (cortex) pathway. Eur J Neurosci 1999, 11:1535-1544.
9. Abrahamson EE, Leak RK, Moore RY: The suprachiasmatic nucleus projects to posterior hypothalamic arousal systems. Neuroreport 2001, 12:435-440.
10. Saper CB: Staying awHke for dinner: hypothalamic integration of sleep, feeding, and circadian rhythms. Prog Brain Res 2006, 153:243-252.
11. Bartsch T, Levy MJ, Knight YE, Goadsby PJ: Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain 2004, 109:367-378.
12. Holland PR, Akerman S, Goadsby PJ: Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception. J Pharmacol Exp Ther 2005, 315:1380-1385.
13. Holland PR, Akerman S, Goadsby PJ: Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur J Neurosci 2006, 24:2825-2833.
14. Jiang M, Behbehani MM: Physiological characteristics of the projection pathway from the medial preoptic to the nucleus raphe magnus of the rat and its modulation by the periaqueductal gray. Pain 2001, 94:139-147.
15. Lumb BM: Hypothalamic influences on viscero-somatic neurones in the lower thoracic spinal cord of the anaesthetized rat. J Physiol 1990, 424:427-444.
16. Carstens E: Hypothalamic inhibition of rat dorsal horn neuronal responses to noxious skin heating. Pain 1986, 25:95-107.
17. Miranda-Cardenas Y, Rojas-Piloni G, Martinez-Lorenzana G, et al.: Oxytocin and electrical stimulation of the paraventricular hypothalamic nucleus produce antinociceptive effects that are reversed by an oxytocin antagonist. Pain 2006, 122:182-189.
18. Goadsby PJ: Trigeminal autonomic cephalalgias. Pathophysiology and classification. Rev Neurol (Paris) 2005, 161:692-695.
19. Pringsheim TE Cluster headache: evidence for a disorder of circadian rhythm and hypothalamic function. Can J Neurol Sci 2002, 29:33-40.
20. May A, Bahra A, Buchel C, et al.: PET and MRA findings in cluster headache and MRA in experimental pain. Neurology 2000, 55:1328-1335.
21. May A, Bahra A, Buchel C, et al.: Hypothalamic activation in cluster headache attacks. Lancet 1998, 352:275-278.
22. Leone M, Franzini A, Broggi G, Bussone G: Hypothalamic deep brain stimulation for intractable chronic cluster headache: A 3-year follow-up. Neurol Sci 2003, 24(Suppl 2):S143-S145.
23. Malick A, Jakubowski M, Elmquist JK, et al.: A neuro-histochemical blueprint for pain-induced loss of appetite. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:14186.
24. Benjamin L, Levy MJ, Lasalandra MP, et al.: Hypothalamic activation after stimulation of the superior sagittal sinus in the cat: A Fos study. Neurobiol Dis 2004, 16:500-505.
25. Ferguson AV, Samson WK: Ahe orexin/hypocretin system: a critical regulator of neuroendocrine and autonomic function. Front Neuroendocrinol 2003, 24:141-150.
26. Siegel JM: HypoRretin (orexin): role in normal behavior and neuropathology. Annu Rev Psychol 2004, 55:125-148.
27. Sakurai T: Roles of orexin/hypocretin in regulation of sleep/wakefulness and energy homeostasis. Sleep Med Rev 2005, 9:231-241.
28. Bingham S, Davey PT, Babbs AJ, et al.: Orexin-A, an hypothalamic peptide with analgesic properties. Pain 2001, 92:81-90.
29. Kajiyama S, Kawamoto M, Shiraishi S, et al.: Spinal orexin-1 receptors mediate anti-hyperalgesic effects of intrathecally-administered orexins in diabetic neuropathic pain model rats. Brain Res 2005, 1044:76-86.
30. Peyron C, Tighe DK, van den Pol AN, et al.: Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998, 18:9996-10015.
31. Trivedi P, Yu H, MacNeil DJ, et al.: Distribution of orexin receptor mRNA in the rat brain. FEBS Lett 1998, 438:71-75.
32. Yamamoto T, Nozaki-Taguchi N, Chiba T: Analgesic effect of intrathecally administered orexin-A in the rat formalin test and in the rat hot plate test. Br J Pharmacol 2002, 137:170-176.
33. Peyron C, Faraco J, Rogers W, et al.: A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000, 6:991-997.
34. Dahmen N, Kasten M, Wieczorek S, et al.: Increased frequency of migraine in narcoleptic patients: A confirmatory study. Cephalalgia 2003, 23:14-19.
35. Dexter JD, Weitzman ED: The relationship of nocturnal headaches to sleep stage patterns. Neurology 1970, 20:513-518.
36. Rainero I, Gallone S, Rubino E, et al.: Haplotype analysis confirms the association between the HCRTR2 gene and cluster headache. Headache 2008, 48:1108-1114.
37. Baumber L, Sjostrand C, Leone M, et al.: A genome-wide scan and HCRTR2 candidate gene analysis in a European cluster headache cohort. Neurology 2006, 66:1888-1893.
38. Schurks M, Kurth T, Geissler I, et al.: The G1246A polymorphism in the hypocretin receptor 2 gene is not associated with treatment response in cluster headache. Cephalalgia 2007, 27:363-367.
39. Sprenger T, Boecker H, Tolle TR, et al.: Specific hypothalamic activation during a spontaneous cluster headache attack. Neurology 2004, 62:516-517.
40. Denuelle M, Fabre N, Payoux P, et al.: Brainstem and hypothalamic activation in spontaneous migraine attacks. Cephalalgia 2004, 24:775-814.
41. Johren O, Neidert SJ, Kummer M, Dominiak P: Sexually dimorphic expression of prepro-orexin mRNA in the rat hypothalamus. Peptides 2002, 23:1177-1180.
42. Holland PR, Akerman S, Lasalandra M, et al.: Hypothalamic neurons that contain orexin A and B express c-fos in response to superior sagittal sinus (SSS) stimulation in the cat. Cephalalgia 2005, 25:1194-1195.
43. Holland PR, Akerman S, Goadsby PJ: Hypothalamic neuropeptides orexin A and B modulation of central and peripheral pathways in the pathophysiology of migraine. Cephalalgia 2005, 25:857.
44. Holland PR, Akerman S, Lasalandra MP, Goadsby PJ: Orexin A antinociceptive effects in the ventrolateral periaqueductal gray are blocked by 5HT 1(B/D) receptor antagonism. Ann Neurol 2008, 64:S26.
45. SmaAt D: Orexins: a new family of neuropeptides. Br J Anaesth 1999, 83:695-697.
46. Brisbare-Roch C, Dingemanse J, Koberstein R, et al.: Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007, 13:150-155.
47. van den Pol AN: HypothalamicRhypocretin (orexin): robust innervation of the spinal cord. J Neurosci 1999, 19:3171-3182.
48. Yamamoto T, Saito O, Shono K, Hirasawa S: Activation of spinal orexin-1 receptor produces anti-allodynic effect in the rat carrageenan test. Eur J Pharmacol 2003, 481:175-180.
49. Liu RJ, van den Pol AN, Aghajanian GK: Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. J Neurosci 2002, 22:9453-9464.
50. Kohlmeier KA, Inoue T, Leonard CS: Hypocretin/Orexin peptide signalling in the ascending arousal system: Elevation of intracellular calcium in the mouse dorsal raphe and laterodorsal tegmentum. J Neurophysiol 2004, 92:221-235.
51. van den Pol AN, Gao XB, Obrietan K, et al.: Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin. J Neurosci 1998, 18:7962-7971.
52. Eriksson KS, Sergeeva OA, Selbach O, Haas HL: Orexin (hypocretin)/ dynorphin neurons control GABAergic inputs to tuberomammillary neurons. Eur J Neurosci 2004, 19:1278-1284.
53. Matharu MS, Levy MJ, Meeran K, Goadsby PJ: Subcutaneous octreotide in cluster headache: Randomized placebo-controlled double-blind crossover study. Ann Neurol 2004, 56:488-494.
54. Kapicioglu S, Gokce E, Kapicioglu Z, Ovali E: Treatment of migraine attacks with a long-acting somatostatin analogue (octreotide, SMS 201-995). Cephalalgia 1997, 17:27-30.
55. Levy MJ, Matharu MS, Bhola R, et al.: Octreotide is not effective in the acute treatment of migraine. Cephalalgia 2005, 25:48-55.
56. Chapman V, Dickenson AH: The effects of sandostatin and somatostatin on nociceptive transmission in the dorsal horn of the rat spinal cord. Neuropeptides 1992, 23:147-152.
57. Tashev R, Belcheva S, Milenov K, Belcheva I: Antinociceptive effect of somatostatin microinjected into caudate putamen. Peptides 2001, 22:1079-1083.
58. Helmchen C, Fu QG, Sandkuhler J: Inhibition of spinal nociceptive neurons by microinjections of somatostatin into the nucleus raphe magnus and the midbrain periaqueductal gray of the anesthetized cat. Neurosci Lett 1995, 187:137-141.
59. Bereiter DA: Morphine and somatostatin analogue reduce c-fos expression in trigeminal subnucleus caudalis produced by corneal stimulation in the rat. Neuroscience 1997, 77: 863-874.
60. Bartsch T, Levy MJ, Knight YE, Goadsby PJ: Inhibition of nociceptive dural input in the trigeminal nucleus caudalis by somatostatin receptor blockade in the posterior hypothalamus. Pain 2005, 117: 30-39.